ORIAHNN (COPACKAGED) — FDA application NDA213388
Listed sponsor: ABBVIE · ABBV company profile · exact_unique
Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.
FDA application facts
| Product | FDA-listed trade name | Active ingredient | Dosage form | Route | Strength | Marketing status | TE code | RLD |
|---|---|---|---|---|---|---|---|---|
| 001 | ORIAHNN (COPACKAGED) | ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM | CAPSULE | ORAL | EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE | Prescription | not listed | Yes |
Product, form, strength, reference-drug and marketing-status fields: Drugs@FDA data files; TE and RLD fields: Orange Book data files. Retrieved 2026-08-07.
Orange Book patent and exclusivity listings
| Listing | Product | Descriptive date | Flags/code |
|---|---|---|---|
| Patent 11459305 | 001 | listed patent expiry date: 2028-11-07 | drug product, U-2842 |
| Patent 7419983 | 001 | listed patent expiry date: 2029-07-06 | drug substance, drug product |
| Patent 10881659 | 001 | listed patent expiry date: 2034-03-14 | U-2842 |
| Patent 11045470 | 001 | listed patent expiry date: 2034-03-14 | U-2842 |
| Patent 12083227 | 001 | listed patent expiry date: 2038-08-20 | drug product, U-2842 |
| Patent 11542239 | 001 | listed patent expiry date: 2039-07-23 | drug substance, drug product |
| Patent 11690845 | 001 | listed patent expiry date: 2040-08-27 | U-3655 |
Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.
Compound cross-links
- ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM · UNII not resolved · no lmmol compound match
Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.
Related pages
Sponsor company · FDA-approved application index
Peer clusters: Large-cap biopharma
Sources: Drugs@FDA · Orange Book · openFDA application record. FDA data retrieved 2026-08-07.
Regulatory listing data as published by FDA; not medical or investment advice.